CLOV-V6

Indications

• Warts
• Plantar warts
• Verrucas
• Umbilical granulomas

Dosage

Children: Apply twice daily for up to 3 consecutive days. Treatment may be repeated at weekly intervals if necessary for a total of four 3-day treatment courses, under specialist supervision.

Adults: Apply twice daily to the lesion for a maximum of 3 applications. Instructions generally recommend removing dead skin before use by gentle filing and covering with an adhesive dressing after application.

Mechanism of action

Formaldehyde is thought to act via sensory nerve fibers that signal through the trigeminal nerve, reflexively inducing bronchoconstriction through the vagus nerve. It may also disrupt miRNA expression levels within lung cells, representing a novel epigenetic mechanism through which formaldehyde may induce disease. Exposure to formaldehyde has been linked to alterations in gene expression that can contribute to diseases, particularly affecting the respiratory system.

Pharmacodynamics

Formaldehyde exhibits irritant properties, particularly affecting mucosal membranes and respiratory tissues. Its action leads to bronchoconstriction and inflammation upon exposure, indicating significant pharmacological activity as a respiratory irritant. Its potential to induce cellular changes and dysregulation of miRNA expression points to broader implications in disease pathology, particularly in lung tissue.

Pharmacokinetics

Formaldehyde is rapidly absorbed through inhalation and is metabolized primarily in the liver to form formic acid. Its short half-life and high reactivity limit its systemic exposure. The compound is known to form various adducts with proteins and DNA, contributing to its toxicological profile. Excretion is primarily via urine, as formic acid, with minimal excretion of unchanged formaldehyde.

Contra-indications

• Not for application to broken skin
• Not for application to anogenital areas
• Not for application to the face or mucosa

Adverse effects

• Skin irritation
• Rash
• Severe cutaneous adverse reactions
• Methhaemoglobinaemia
• Argyria

Precautions

• Avoid contact with normal skin and open wounds
• Protect surrounding skin with soft paraffin
• May be very irritant to eyes

Pregnancy

Avoid use during pregnancy due to potential harmful effects.

Breast-feeding

Avoid use during breastfeeding due to potential harmful effects.

Storage

Store in a cool, dry place away from light.

Formulations

• Formaldehyde solution 4% (Buffered)
• Formaldehyde liquid 10%

Indications

• Disinfection of skin and mucous membranes
• Preservative in pharmaceutical formulations
• Antiseptic in medical and veterinary applications

Dosage

Children: Refer to BNF for Children for specific dosing recommendations tailored to paediatric patients.

Adults: Refer to BNF for specific dosing guidelines based on the formulation and condition being treated.

Mechanism of action

Metacresol exhibits antimicrobial activity by disrupting the cell membrane of bacteria, leading to cell lysis and death. Its effectiveness is attributed to its ability to denature proteins and dissolve lipid membranes, which is critical for maintaining the integrity of bacterial cells.

Pharmacodynamics

The pharmacodynamic effects of metacresol are primarily related to its antiseptic and disinfectant properties. It is effective against a wide range of pathogens, including bacteria, fungi, and some viruses. The concentration and exposure time are key factors that influence its efficacy, with higher concentrations generally leading to increased antimicrobial activity.

Pharmacokinetics

Metacresol is absorbed through the skin and mucous membranes, and its systemic absorption can vary based on the route of administration. It is metabolized primarily in the liver and excreted in the urine. The half-life and excretion rates can vary significantly based on individual factors such as age and liver function. Precautions should be taken to minimize exposure due to its potential toxicity.

Pregnancy

There is limited data on the use of metacresol in pregnancy. It is advisable to avoid use unless the potential benefits outweigh the risks.

Breast-feeding

Caution is advised when using metacresol during breastfeeding, as the effects on the nursing infant are not well studied.

Storage

Store in a tightly sealed container at room temperature, away from light and moisture.

Indications

• Bacterial infections
• Inflammatory conditions
• Diabetes management
• Certain skin conditions

Dosage

Children: Refer to the BNF for Children for appropriate paediatric dosing, as it varies significantly based on age, weight, and indication.

Adults: Refer to specific BNF guidance for adult dosing, as it varies by the specific sulphonated drug and indication.

Mechanism of action

The mechanism of action of sulphonated drugs can vary widely depending on the specific compound. Generally, they may inhibit bacterial enzyme systems, interfere with metabolic pathways, or modulate inflammatory responses. For instance, sulfonamides, a subclass of sulphonated drugs, act as competitive inhibitors of the bacterial enzyme dihydropteroate synthase, which is involved in folate synthesis. By blocking this enzyme, sulfonamides prevent the production of folate, which is essential for nucleic acid synthesis in bacteria, leading to bacterial cell death.

Pharmacodynamics

Sulphonated drugs typically exhibit broad-spectrum antimicrobial activity. They can also have anti-inflammatory properties and may influence glucose metabolism, leading to their use in controlling blood sugar levels in diabetic patients. The efficacy of these drugs can be affected by factors such as the presence of resistance mechanisms in bacteria, the patient's immune response, and concurrent medications.

Pharmacokinetics

The pharmacokinetics of sulphonated drugs vary based on the specific agent but generally includes absorption through the gastrointestinal tract, with peak plasma concentrations occurring within a few hours post-administration. They are often metabolized in the liver, and their metabolites can be excreted in urine. The half-life can range from several hours to days, depending on the drug and patient-specific factors such as age, renal function, and co-morbidities.

Adverse effects

• Allergic reactions
• Skin rashes
• Gastrointestinal disturbances
• Hematological abnormalities
• Liver toxicity

Interactions

• May interact with anticoagulants, increasing risk of bleeding
• May affect the metabolism of certain antiepileptic drugs
• Potential interactions with other medications metabolized by the liver

Precautions

• Use with caution in patients with pre-existing liver or kidney disease
• Monitor for signs of hypersensitivity reactions
• Periodic blood counts may be necessary due to potential hematological effects

Pregnancy

Use only if clearly needed, as safety in pregnancy has not been established.

Breast-feeding

Caution is advised; consult healthcare provider for recommendations.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Mechanism of action

Formaldehyde is thought to act via sensory nerve fibers that signal through the trigeminal nerve to reflexively induce bronchoconstriction through the vagus nerve. Exposure to formaldehyde, a known air toxic, is associated with cancer and lung disease. Despite the adverse health effects of formaldehyde, the mechanisms underlying formaldehyde-induced disease remain largely unknown. Research has uncovered microRNAs (miRNAs) as key posttranscriptional regulators of gene expression that may influence cellular disease state. Although studies have compared different miRNA expression patterns between diseased and healthy tissue, this is the first study to examine perturbations in global miRNA levels resulting from formaldehyde exposure. We investigated whether cellular miRNA expression profiles are modified by formaldehyde exposure to test the hypothesis that formaldehyde exposure disrupts miRNA expression levels within lung cells, representing a novel epigenetic mechanism through which formaldehyde may induce disease. Human lung epithelial cells were grown at air-liquid interface and exposed to gaseous formaldehyde at 1 ppm for 4 hr. Small RNAs and protein were collected and analyzed for miRNA expression using microarray analysis and for interleukin (IL-8) protein levels by enzyme-linked immunosorbent assay (ELISA). RESULTS: Gaseous formaldehyde exposure altered the miRNA expression profiles in human lung cells. Specifically, 89 miRNAs were significantly down-regulated in formaldehyde-exposed samples versus controls. Functional and molecular network analysis of the predicted miRNA transcript targets revealed that formaldehyde exposure potentially alters signaling pathways associated with cancer, inflammatory response, and endocrine system regulation. IL-8 release increased in cells exposed to formaldehyde, and results were confirmed by real-time polymerase chain reaction. Formaldehyde alters miRNA patterns that regulate gene expression, potentially leading to the initiation of a variety of diseases. Formaldehyde at high concentrations is a contributor to air pollution. It is also an endogenous metabolic product in cells, and when beyond physiological concentrations, has pathological effects on neurons. Formaldehyde induces mis-folding and aggregation of neuronal tau protein, hippocampal neuronal apoptosis, cognitive impairment and loss of memory functions, as well as excitation of peripheral nociceptive neurons in cancer pain models. Intracellular calcium ([Ca(2+)](i)) is an important intracellular messenger, and plays a key role in many pathological processes. The present study aimed to investigate the effect of formaldehyde on [Ca(2+)](i) and the possible involvement of N-methyl-D-aspartate receptors (NMDARs) and T-type Ca(2+) channels on the cell membrane. METHODS: Using primary cultured hippocampal neurons as a model, changes of [Ca(2+)](i) in the presence of formaldehyde at a low concentration were detected by confocal laser scanning microscopy. Formaldehyde at 1 mmol/L approximately doubled [Ca(2+)](i). (2R)-amino-5-phosphonopentanoate (AP5, 25 umol/L, an NMDAR antagonist) and mibefradil (MIB, 1 umol/L, a T-type Ca(2+) channel blocker), given 5 min after formaldehyde perfusion, each partly inhibited the formaldehyde-induced increase of [Ca(2+)](i), and this inhibitory effect was reinforced by combined application of AP5 and MIB. When applied 3 min before formaldehyde perfusion, AP5 (even at 50 umol/L) did not inhibit the formaldehyde-induced increase of [Ca(2+)](i), but MIB (1 umol/L) significantly inhibited this increase by 70%. These results suggest that formaldehyde at a low concentration increases [Ca(2+)](i) in cultured hippocampal neurons; NMDARs and T-type Ca(2+) channels may be involved in this process. /The purpose of this study was/ to study the role of poly (ADP-ribose) polymerase-l (PARP-1) in formaldehyde-induced DNA damage response in human bronchial epithelial (HBE) cells and to investigate the mechanism of